ClinicalTrials.gg
Enrolling by invitationNCT06450834Ostene VIBeUpdated Sep 4, 2026

Ostene in Thoracolumbar Decompression and Fusion Evaluated With VIBE

An observational study in Intraoperative Complications, Intraoperative Bleeding and Intraoperative Blood Loss, sponsored by University of Maryland, Baltimore. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years to 88 Years. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by University of Maryland, Baltimore · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
173
Ages
18 Years to 88 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Intraoperative Complications with a site in United States — 4 open to participants now, 4 under way, none of them phase 3. Intraoperative Complications · United States.

Started
2025
with 2 others
Observational
7 of 13
2 open now
Registered
11th of 13
by date
Lead sponsor
1 of 13
University of Maryland, Baltimore

Among the 13 studies in Intraoperative Complications with a site in United States, this one is one of 3 that started in 2025, is one of 7 observational ones, and was the 11th registered.

Intraoperative Complications

92 studies on the registry are indexed under Intraoperative Complications; 19 are open to participants now.

Browse Intraoperative Complications studies →

Open to participants now

4 of the 13 studies in Intraoperative Complications with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Intraoperative Complications studies recruiting now, 6 (43%) set no upper age limit and 6 (43%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 88 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Intraoperative Complications with a site in United States, or all of them as a file.
02

Study summary

In spine surgery, it is important to try to minimize bleeding. In particular, spine surgery often involves inserting hardware into bone, and/or removing bone in the spine. Because the bone in the spine contains blood vessels, there can often be bleeding from the bone itself that is difficult to stop completely. One way to stop bone bleeding is through the use of wax-like materials, which plug the bleeding bone and act as a physical barrier to stop bleeding. One example is Ostene bone hemostasis material, which has the advantage of being "water soluble", meaning it will dissolve naturally over time. The purpose of this study is to evaluate how well Ostene does at decreasing bleeding, by using a recognized scale called the validated intraoperative bleeding severity scale, abbreviated as "VIBe". In this study, the investigators will record the bleeding severity throughout multiple time points in surgery using this scale, and then the investigators will compare the measurements to patients in the past who did not receive Ostene. Overall, this research will help measure how well Ostene decreases bleeding.

Read the detailed description
  • Patients will be screened prior to surgery for inclusion and exclusion criteria.
  • If eligible, patients will be approached in the preoperative area or clinic location to consent or refuse participation in the study.
  • Baseline characteristics will be collected via a combination of patient preoperative survey and manual chart review.
  • Patients will undergo the normal surgical standard of care, receiving Ostene intraoperatively as determined appropriate by the attending spine surgeon during the procedure.
  • It is anticipated that Ostene will be used specifically during the bony work/laminectomy phase preceding decompression. Of note, this material is now considered standard of care by our principal investigator and would be used regardless of study participation.
  • Other hemostatic agents will be used according to the typical standard of care.
  • A trained research coordinator will be present to determine VIBe scores during 6 key surgical phases: 1) exposure, 2) bony work/laminectomy, 3) decompression, 4) instrumentation, 5) fusion, and 6) closure. Agreement will be obtained from the operating surgeon.
  • For all phases, the maximum VIBe score during each phase will be recorded.
  • Surgical information will be documented from the operative note.
  • Patients will receive the normal standard of care postoperatively including measure(s) of their hemoglobin/hematocrit and postoperative drain output.
  • Data on postoperative outcomes/complications will be collected from the electronic medical record.
  • A propensity-score matched cohort analysis will be constructed to compare patients who received Ostene to patients who did not receive Ostene (will use data from past study conducted from 2021-April 2023 to construct matched control cohort).

    • There will be no group assignment in this study
    • There will be no placebo group or randomization
    • Patient data from a past study will be used as a control comparator
03

Conditions studied

  • Intraoperative Complications
  • Intraoperative Bleeding
  • Intraoperative Blood Loss
  • Hemostasis
  • Blood Transfusion
  • Postoperative Hemorrhage
  • Postoperative Complications
  • Spine Fusion
  • Thoracolumbar Spine
04

Who can participate

Ages eligible
18 Years to 88 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients 18 to 88 years old undergoing elective thoracolumbar decompression, instrumentation, and fusion procedures with an open, posterior approach and without indication for trauma, tumor, or suspected/confirmed infection, emergent triage status, an anterior or lateral approach, or a minimally invasive approach

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients 18 to 88 years old
  • Elective thoracolumbar decompression, instrumentation, and fusion procedure
  • Open, posterior approach
  • Patients included for analysis in a related prior study which had enrollment criteria congruent with the current study

Exclusion criteria

Exclusion Criteria:

  • Indication for trauma, tumor, or suspected/confirmed infection
  • Emergent triage status
  • Anterior or lateral approach
  • Minimally invasive approach
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
173 participants (estimated)
Patient registry
No

Groups and cohorts

  • Ostene

    Patients who received Ostene during their thoracolumbar spine surgery

    Device: Ostene

  • No Ostene

    Propensity score matched cohort from previous study that did not receive Ostene during their spine surgery

Interventions

  • DeviceOstene

    Soluble Bone Hemostasis Implant Material

06

What researchers measure

Primary outcomes

  1. Intraoperative blood transfusion

    binary and number of units

    Time frame: Intraoperative

  2. postoperative blood transfusion

    binary and number of units

    Time frame: 3 days

Secondary outcomes

  1. preoperative hemoglobin/hematocrit

    Time frame: Immediately preoperative

  2. 3 days before surgery of preoperative hemoglobin/hematocrit

    Time frame: 3 days

  3. postoperative hemoglobin/hematocrit

    Time frame: 3 days

  4. days after surgery of postoperative hemoglobin/hematocrit

    Time frame: 3 days

  5. postoperative drain output

    average daily drain output, total drain output

    Time frame: From the first day postoperatively then measured daily, until the patient is discharged, up to 1 year

  6. Presence of Deep Vein Thrombosis

    Time frame: From the date of surgery until 1 year follow up appointment

  7. Presence of Pulmonary Embolism

    Time frame: From the date of surgery until 1 year follow up appointment

  8. Presence of postoperative complication requiring medical intervention

    Time frame: From the date of surgery until 1 year follow up appointment

  9. length of stay

    Time frame: From the date of surgery until discharge up to 1 year

  10. 30-day readmissions

    Time frame: readmission within 30 days

  11. 30-day reoperations

    Time frame: reoperation within 30 days

  12. 30-day emergency department visits

    Time frame: ED visits within 30 days

  13. cost

    total hospital billing for procedure and total episode of stay and/or insurance reimbursement amount

    Time frame: From the date of surgery until discharge up to 1 year

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — There is currently no plan to share IPD data with any other researchers.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Jun 2027, 29 months after the start.

Of 23 observational studies under Intraoperative Complications, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 17. This study's planned 29 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2024
First posted
Jun 10, 2024
StartActual
Jan 17, 2025
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06450834
Responsible party
Steven Ludwig (Professor of Orthopaedics, University of Maryland, Baltimore) — Principal investigator
First posted
Jun 10, 2024
Start date
Jan 17, 2025
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Sep 4, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion